Purpose: To determine the long-term efficacy of the anti-tumor necrosis factor (TNF) agents,
infliximab (IFX) and adalimumab (ADA), in pediatric luminal Crohn's disease (CD) by …

Objective A significant proportion of patients with initial response to Inflximab (IFX),
subsequently lose response (LOR). Multicentre paediatric studies report LOR in 33% to 50 …

Abstract Background & Aims We aim to provide guidance for medical treatment of luminal
Crohn's disease in children. Methods We performed a systematic search of publication …

Background Infliximab induces and maintains clinical remission in children with Crohn's
disease (CD), but specifically pediatric long-term data remain sparse. Methods Patients (N …

Abstract Background and Aims: We aimed to compare the efficacy of combined
immunosuppression in terms of mucosal healing in paediatric patients with moderate-to …

METHODS: Patients younger than 18 years and diagnosed between 2009 and 2019 were
included in this retrospective cohort study. Clinical, endoscopic, histological, and laboratory …

Objective In newly diagnosed paediatric patients with moderate-to-severe Crohn's disease
(CD), infliximab (IFX) is initiated once exclusive enteral nutrition (EEN), corticosteroid and …

Background & Aims Tumor necrosis factor inhibitors, including infliximab and adalimumab,
are a mainstay of pediatric Crohn's disease therapy; however, nonresponse and loss of …

Biologic agents with various mechanisms against Crohn's disease (CD) have been released
and are widely used in clinical practice. However, two anti-tumor necrosis factor (TNF) …

Abstract Background and Aims Treatment guidelines for paediatric Crohn's disease [CD]
suggest early use of anti-tumour necrosis factor alpha [anti-TNFα] in high-risk individuals …